

Monica Mazzarino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8156315/publications.pdf>

Version: 2024-02-01

60
papers

1,115
citations

430874

18
h-index

454955

30
g-index

63
all docs

63
docs citations

63
times ranked

890
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro metabolic profile of mexedrone, a mephedrone analog, studied by high- and low-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2022, 14, 269-276.	2.6	5
2	Urinary excretion and effects on visual placing response in mice of gamma-valero-lactone, an alternative to gamma-hydroxy-butyrate for drug-facilitated sexual assault. <i>Emerging Trends in Drugs, Addictions, and Health</i> , 2022, 2, 100028.	1.1	3
3	Urinary excretion profile of methiopropamine in mice following intraperitoneal administration: A liquid chromatography-tandem mass spectrometry investigation. <i>Drug Testing and Analysis</i> , 2021, 13, 91-100.	2.6	10
4	Influence of Saw palmetto and <i>Pygeum africana</i> extracts on the urinary concentrations of endogenous anabolic steroids: Relevance to doping analysis. <i>Phytomedicine Plus</i> , 2021, 1, 100005.	2.0	2
5	Metabolic profile of the synthetic drug 4,4-dimethylaminorex in urine by LC-MS-based techniques: selection of the most suitable markers of its intake. <i>Forensic Toxicology</i> , 2021, 39, 89-100.	2.4	7
6	Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 195, 113849.	2.8	15
7	Urinary Elimination of Ecdysterone and Its Metabolites Following a Single-Dose Administration in Humans. <i>Metabolites</i> , 2021, 11, 366.	2.9	8
8	Effects of the administration of miconazole by different routes on the biomarkers of the œsteroidal module of the Athlete Biological Passport. <i>Drug Testing and Analysis</i> , 2021, 13, 1712-1726.	2.6	6
9	Worsening of the Toxic Effects of (±)Cis-4,4-DMAR Following Its Co-Administration with (±)Trans-4,4-DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8771.	4.1	3
10	Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1185, 122989.	2.3	2
11	UPLC-MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine. <i>Journal of Analytical Toxicology</i> , 2021, 45, 184-194.	2.8	14
12	How reliable is dietary supplement labelling? Experiences from the analysis of ecdysterone supplements. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112877.	2.8	12
13	Targeting the administration of ecdysterone in doping control samples. <i>Forensic Toxicology</i> , 2020, 38, 172-184.	2.4	31
14	Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of phthalates and bisphenol a in serum, urine and follicular fluid. <i>Clinical Mass Spectrometry</i> , 2020, 18, 54-65.	1.9	12
15	Carbon isotopic characterization of prednisolone and prednisone pharmaceutical formulations: Implications in antidoping analysis. <i>Drug Testing and Analysis</i> , 2020, 12, 1587-1598.	2.6	6
16	Detection and quantitation of ecdysterone in human serum by liquid chromatography coupled to tandem mass spectrometry. <i>Steroids</i> , 2020, 157, 108603.	1.8	7
17	Prescription Drug Misuse in œClubbersœ and Disco Goers in Ibiza. <i>Frontiers in Psychiatry</i> , 2020, 11, 592594.	2.6	5
18	Urinary excretion profile of prednisone and prednisolone after different administration routes. <i>Drug Testing and Analysis</i> , 2019, 11, 1601-1614.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. <i>Archives of Toxicology</i> , 2019, 93, 1807-1816.	4.2	75
20	Detection of recombinant insulins in human urine by liquid chromatography–electrospray ionization tandem mass spectrometry after immunoaffinity purification based on monolithic microcolumns. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 8153-8162.	3.7	9
21	Detection of 5 α -reductase inhibitors by UPLC–MS/MS: Application to the definition of the excretion profile of dutasteride in urine. <i>Drug Testing and Analysis</i> , 2019, 11, 1737-1746.	2.6	6
22	Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes. <i>Drug Testing and Analysis</i> , 2018, 10, 984-994.	2.6	3
23	A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009. <i>Drug Testing and Analysis</i> , 2018, 10, 1670-1681.	2.6	15
24	Drug–drug interaction and doping: Effect of non-prohibited drugs on the urinary excretion profile of methandienone. <i>Drug Testing and Analysis</i> , 2018, 10, 1554-1565.	2.6	6
25	The effect of zolpidem on cognitive function and postural control at high altitude. <i>Sleep</i> , 2018, 41, .	1.1	2
26	Liposomes as potential masking agents in sport doping. Part 2: Detection of liposome-entrapped haemoglobin by flow cytofluorimetry. <i>Drug Testing and Analysis</i> , 2017, 9, 208-215.	2.6	4
27	Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normal-phase liquid chromatography–tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2017, 9, 75-86.	2.6	4
28	Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography–mass spectrometry profiling: Relevance to doping control analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 555-568.	2.8	16
29	Doping control container for urine stabilization: a pilot study. <i>Drug Testing and Analysis</i> , 2017, 9, 699-712.	2.6	7
30	<i>In vitro</i> evaluation of the effects of anti-fungals, benzodiazepines and non-steroidal anti-inflammatory drugs on the glucuronidation of 19 α -norandrosterone: implications on doping control analysis. <i>Drug Testing and Analysis</i> , 2016, 8, 930-939.	2.6	11
31	Drug-drug interactions and masking effects in sport doping: influence of miconazole administration on the urinary concentrations of endogenous anabolic steroids. <i>Forensic Toxicology</i> , 2016, 34, 386-397.	2.4	13
32	Multianalyte LC–MS-based methods in doping control: what are the implications for doping athletes?. <i>Bioanalysis</i> , 2016, 8, 1129-1132.	1.5	8
33	A multi-targeted liquid chromatography–mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 117, 47-60.	2.8	22
34	Drug Use on Mont Blanc: A Study Using Automated Urine Collection. <i>PLoS ONE</i> , 2016, 11, e0156786.	2.5	16
35	Development and validation of a liquid chromatography–mass spectrometry procedure after solid-phase extraction for detection of 19 doping peptides in human urine. <i>Forensic Toxicology</i> , 2015, 33, 321-337.	2.4	31
36	Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies. <i>Toxicology in Vitro</i> , 2015, 30, 331-340.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Narrowing the gap between the number of athletes who dope and the number of athletes who are caught: scientific advances that increase the efficacy of antidoping tests. <i>British Journal of Sports Medicine</i> , 2014, 48, 833-836.	6.7	21
38	Acute effects of physical exercise and phosphodiesterase type 5 inhibition on serum 11 β -hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study. <i>Endocrine</i> , 2014, 47, 952-958.	2.3	10
39	Drug-drug interaction and doping, part 2: An <i>in vitro</i> study on the effect of non-prohibited drugs on the phase I metabolic profile of stanozolol. <i>Drug Testing and Analysis</i> , 2014, 6, 969-977.	2.6	23
40	Drug-drug interaction and doping, part 1: An <i>in vitro</i> study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene. <i>Drug Testing and Analysis</i> , 2014, 6, 482-491.	2.6	9
41	A liquid chromatography-mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. <i>Analytica Chimica Acta</i> , 2014, 837, 70-82.	5.4	36
42	A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: Application to the characterization of the metabolic profile and stability of formoterol in urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 931, 75-83.	2.3	15
43	Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/MS following <i>in vitro</i> and excretion studies. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 5467-5487.	3.7	31
44	Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2011, 127, 248-254.	2.5	14
45	Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: Endogenous steroids urinary profile after multiple oral doses. <i>Steroids</i> , 2011, 76, 1400-1406.	1.8	28
46	Screening and confirmation analysis of stimulants, narcotics and beta-adrenergic agents in human urine by hydrophilic interaction liquid chromatography coupled to mass spectrometry. <i>Journal of Chromatography A</i> , 2011, 1218, 8156-8167.	3.7	42
47	A rapid analytical method for the detection of plasma volume expanders and mannitol based on the urinary saccharides and polyalcohols profile. <i>Drug Testing and Analysis</i> , 2011, 3, 896-905.	2.6	5
48	Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 529-541.	3.7	9
49	Urine stability and steroid profile: Towards a screening index of urine sample degradation for anti-doping purpose. <i>Analytica Chimica Acta</i> , 2011, 683, 221-226.	5.4	44
50	A simple and rapid pre-confirmation method to distinguish endogenous human haemoglobin from synthetic haemoglobin-based oxygen carriers in doping control. <i>Electrophoresis</i> , 2011, 32, 2915-2918.	2.4	5
51	A rapid screening LC-MS/MS method based on conventional HPLC pumps for the analysis of low molecular weight xenobiotics: application to doping control analysis. <i>Drug Testing and Analysis</i> , 2010, 2, 311-322.	2.6	20
52	Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection. <i>Analytica Chimica Acta</i> , 2010, 657, 60-68.	5.4	18
53	Microwave irradiation for a fast gas chromatography-mass spectrometric analysis of polysaccharide-based plasma volume expanders in human urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3024-3032.	2.3	8
54	Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 749-760.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Rapid screening of beta-adrenergic agents and related compounds in human urine for anti-doping purpose using capillary electrophoresis with dynamic coating. <i>Journal of Separation Science</i> , 2009, 32, 3562-3570.	2.5	21
56	A screening method for the detection of synthetic glucocorticosteroids in human urine by liquid chromatography-mass spectrometry based on class-characteristic fragmentation pathways. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 1389-1402.	3.7	61
57	A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 681-698.	3.7	106
58	A Mass Spectrometric Approach for the Study of the Metabolism of Clomiphene, Tamoxifen and Toremifene by Liquid Chromatography Time-of-Flight Spectroscopy. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 171-180.	1.0	40
59	A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 3465-3476.	1.5	91
60	Effect of the systemic versus inhalatory administration of synthetic glucocorticoids on the urinary steroid profile as studied by gas chromatography-mass spectrometry. <i>Analytica Chimica Acta</i> , 2006, 559, 30-36.	5.4	18